# TULSA-PRO

Type: Product

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/tulsa-pro-product
Canonical HTML page: https://getfinancebrief.com/entity/tulsa-pro-product

## Timeline

- **2026-Q4 (estimated)**: PROF Break-even — Target window for Profound Medical to reach cash-flow neutrality.
- **2026-Q2 (estimated)**: Kura NDA Submission — Anticipated filing for ziftomenib with the FDA.
- **2026-03-05**: Q4 Earnings Release — Both companies report pivotal year-end results.
- **2025-01-01**: CPT Code Activation — Category 1 CPT codes for TULSA-PRO go live in the U.S.

## Recent coverage (2 stories)

### Kura and Profound Signal Commercial Inflection Points in Q4 Results
2026-03-06 05:18:01 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Kura Oncology and Profound Medical reported Q4 2025 results, highlighting a pivotal shift toward commercial execution. Kura is nearing an NDA submission for its lead leukemia candidate, while Profound saw record revenue growth following the first full year of Category 1 CPT code implementation.
Full story: https://getfinancebrief.com/story/kura-oncology-profound-medical-q4-earnings-analysis-2026

### Profound Medical and OptimizeRx Post Strong 2025 Results as Med-Tech Scales
2026-03-06 01:08:45 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Profound Medical and OptimizeRx reported robust fourth-quarter and full-year 2025 financial results, signaling a significant uptick in the adoption of MRI-guided interventions and digital life sciences engagement. The reports highlight a broader recovery in healthcare technology spending and a shift toward precision-based medical outcomes.
Full story: https://getfinancebrief.com/story/profound-medical-optimizerx-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.